BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) 

25 Science Park, Room 561

New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-5606 Fax: 203-624-5627


SEARCH JOBS

View Clinical Trials from BioPharm Insight




Segment
Drug Discovery





 Company News
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Demonstrates Potent In Vitro Activity Of New Antibiotic Class Against Gram Negative ESKAPE Pathogens 9/8/2014 2:44:44 PM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Demonstrate Delafloxacin's Potent And Rapid Antimicrobial Activity Against Neisseria Gonorrhoeae 9/8/2014 10:10:59 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports On PK Profile Of A Single Oral Dose Of Delafloxacin In Support Of U.S. Phase 3 Gonorrhea Program 9/8/2014 7:40:59 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) And Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity Against Complicated Urinary Tract Infection Pathogens 9/8/2014 7:39:38 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Highlighting Delafloxacin And ESKAPE Candidates In Twelve Presentations At 2014 ICAAC Meeting 9/4/2014 10:19:35 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Bolsters Board Of Directors With Appointment Of Christopher Kiritsy 8/15/2014 7:45:00 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports Top-Line Results Showing Equivalent Exposures After Oral and Intravenous Delafloxacin Administration 8/11/2014 10:55:15 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Announces Accepted Abstracts At The 2014 Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 7/24/2014 10:03:57 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Phase 3 Study Of I.V. And Oral Delafloxacin Has Begun Enrolling Patients With Acute Bacterial Skin And Skin Structure Infections 5/5/2014 12:27:16 PM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) To Present At Needham & Company's Annual Healthcare Conference 4/3/2014 1:56:25 PM
12345678